Marllor Biomedical Partners with Wigmore to Distribute Non-Surgical Aesthetic Products
Marllor Biomedical has entered into an exclusive distribution agreement with the UK's leading aesthetics and beauty distributor Wigmore Medical. The agreement will see Wigmore Medical distribute the Marllor Biomedical non-surgical aesthetic products Aqualyx and Alidya.
Marllor Biomedical provide a leading scientific and technical contribution to non-surgical procedures in Aesthetic Medicine and Dermatology. From their Lab in Bologna, Italy, they focus on restoring confidence to patients all over the world with medical aesthetics treatments that treat the root of the problem, helping patients restore beauty from within. Among Marllor Biomedical's portfolio are Aqualyx and Alidya, both widely recognised within the medical aesthetics market.
Aqualyx is a safe, clinically proven, non-surgical treatment designed to contour and refine targeted areas of the body to dissolve localised fat deposits. Aqualyx has been established in the market for over 15 years, with more than 3 million vials sold worldwide. Its consistent clinical performance and high patient satisfaction have made it a trusted choice for medical professionals.
Alidya is the first injectable of its kind specifically developed for the prevention and treatment of cellulite. Alidya targets the underlying causes of cellulite, visibly improving skin texture and tone after just a few sessions. With more than a decade of clinical use, Alidya has become a trusted solution among aesthetic practitioners seeking effective, evidence-based treatments to help patients restore confidence in their appearance.
Statement from Martina Motolese, COO, Marllor Biomedical commented “We are very pleased to formalise our partnership with Wigmore Medical in the UK. For Marllor, this collaboration represents an important strategic step in strengthening our presence in one of Europe’s most dynamic and clinically advanced aesthetic markets. Wigmore’s reputation, educational focus, and deep understanding of the UK medical aesthetics landscape make them an ideal partner for the continued growth of Aqualyx and Alidya. This partnership signifies more than distribution — it reflects a shared commitment to clinical excellence, responsible innovation, and long-term brand building. Together, we aim to further elevate treatment standards, support practitioners through high-level education, and expand patient awareness of evidence-based body treatments.”
“This partnership represents an important step in firmly establishing and securing Marllor’s long-term presence in the UK as a leader in evidence-based injectable treatments. We are incredibly excited to be working with a brand that is committed to building lasting credibility, trust, and leadership within medical aesthetics. Marllor takes a genuinely personal and relationship-led approach to its partnerships, operating very much as an extension of the teams it works with, an ethos that aligns very much with Wigmore Medical’s own values. With Aqualyx and Alidya, we look forward to growing these brands responsibly, supporting practitioners through meaningful education, and raising treatment standards across the UK” added Raffi Eghiayan, CEO, Wigmore Medical
